-
IP addresses are NOT logged in this forum so there's no point asking. Please note that this forum is full of homophobes, racists, lunatics, schizophrenics & absolute nut jobs with a smattering of geniuses, Chinese chauvinists, Moderate Muslims and last but not least a couple of "know-it-alls" constantly sprouting their dubious wisdom. If you believe that content generated by unsavory characters might cause you offense PLEASE LEAVE NOW! Sammyboy Admin and Staff are not responsible for your hurt feelings should you choose to read any of the content here. The OTHER forum is HERE so please stop asking.
Immunotherapy Shows Potential to Treat Deadly Thyroid Cancer
- Thread starter ginfreely
- Start date
A type of immunotherapy appears to be effective in treating a deadly subset of thyroid cancer, according to the results of a clinical trial published in JAMA Oncology.
While they are rare, aggressive thyroid carcinomas can be deadly and have limited treatment options, said Jochen Lorch, MD, professor of Medicine in the Division of Hematology and Oncology, and senior author of the study.
In the current clinical trial, investigators set out to test a combination immunotherapy of the drugs nivolumab and ipilimumab, which prevent cancer from suppressing the immune system.
In the study, 49 patients with different types of aggressive thyroid cancers were given the drugs every two weeks for a maximum of two years. Only 9 percent of patients with differentiated thyroid carcinoma responded to the treatment and those with medullary thyroid carcinoma showed no signs of responding to the treatment, according to the study.
However, patients with anaplastic thyroid carcinoma had a response rate of 30 percent, a significant number considering there are currently no effective treatments for the cancer, Lorch said.
“Among the anaplastic thyroid cancers, we saw three profound responses out of 10 patients, a relatively small exploratory cohort,” said Lorch, who is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “Aplastic thyroid cancer is one of the most aggressive cancers that you can get, with a median survival of roughly four months and no cure rate. To have such a high rate of responses was shocking.”
While the immunotherapy was not effective for all types of thyroid cancers, the response among anaplastic thyroid carcinoma patients merits further study, Lorch said.
Building off this finding, Lorch has launched additional clinical trials for the treatment. He hopes to share his findings soon, he said.
“This has already sparked a number of developments already,” Lorch said. “It has the potential to become a standard of care for this otherwise terrible, rapidly fatal disease.”
The study was supported by the Dana-Farber Cancer Institute, with additional funding from Bristol-Myers Squibb.
CancerMedicine
While they are rare, aggressive thyroid carcinomas can be deadly and have limited treatment options, said Jochen Lorch, MD, professor of Medicine in the Division of Hematology and Oncology, and senior author of the study.
In the current clinical trial, investigators set out to test a combination immunotherapy of the drugs nivolumab and ipilimumab, which prevent cancer from suppressing the immune system.
In the study, 49 patients with different types of aggressive thyroid cancers were given the drugs every two weeks for a maximum of two years. Only 9 percent of patients with differentiated thyroid carcinoma responded to the treatment and those with medullary thyroid carcinoma showed no signs of responding to the treatment, according to the study.
However, patients with anaplastic thyroid carcinoma had a response rate of 30 percent, a significant number considering there are currently no effective treatments for the cancer, Lorch said.
“Among the anaplastic thyroid cancers, we saw three profound responses out of 10 patients, a relatively small exploratory cohort,” said Lorch, who is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “Aplastic thyroid cancer is one of the most aggressive cancers that you can get, with a median survival of roughly four months and no cure rate. To have such a high rate of responses was shocking.”
While the immunotherapy was not effective for all types of thyroid cancers, the response among anaplastic thyroid carcinoma patients merits further study, Lorch said.
Building off this finding, Lorch has launched additional clinical trials for the treatment. He hopes to share his findings soon, he said.
“This has already sparked a number of developments already,” Lorch said. “It has the potential to become a standard of care for this otherwise terrible, rapidly fatal disease.”
The study was supported by the Dana-Farber Cancer Institute, with additional funding from Bristol-Myers Squibb.
CancerMedicine
Last edited:
Similar threads
